Precision Clinical Medicine最新文献_第5页

Dysregulated miRNAs modulate tumor microenvironment associated signaling networks in pancreatic ductal adenocarcinoma. 失调的 miRNA 可调节胰腺导管腺癌中与肿瘤微环境相关的信号网络。

IF 5.3 4区医学

Precision Clinical Medicine Pub Date : 2023-03-10 eCollection Date: 2023-03-01 DOI: 10.1093/pcmedi/pbad004

Tiantian Liu, Zhong Chen, Wanqiu Chen, Ryan Evans, Jane Xu, Mark E Reeves, Michael E de Vera, Charles Wang

{"title":"Dysregulated miRNAs modulate tumor microenvironment associated signaling networks in pancreatic ductal adenocarcinoma.","authors":"Tiantian Liu, Zhong Chen, Wanqiu Chen, Ryan Evans, Jane Xu, Mark E Reeves, Michael E de Vera, Charles Wang","doi":"10.1093/pcmedi/pbad004","DOIUrl":"10.1093/pcmedi/pbad004","url":null,"abstract":"The desmoplastic and complex tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC) has presented tremendous challenges for developing effective therapeutic strategies. Strategies targeting tumor stroma, albeit with great potential, have met with limited success due to the lack of knowledge on the molecular dynamics within the tumor microenvironment (TME). In pursuit of a better understanding of the influence of miRNAs on TME reprogramming and to explore circulating miRNAs as diagnostic and prognostic biomarkers for PDAC, using RNA-seq, miRNA-seq, and single-cell RNA-seq (scRNA-seq), we investigated the dysregulated signaling pathways in PDAC TME modulated by miRNAs from plasma and tumor tissue. Our bulk RNA-seq in PDAC tumor tissue identified 1445 significantly differentially expressed genes with extracellular matrix and structure organization as the top enriched pathways. Our miRNA-seq identified 322 and 49 abnormally expressed miRNAs in PDAC patient plasma and tumor tissue, respectively. We found many of the TME signaling pathways were targeted by those dysregulated miRNAs in PDAC plasma. Combined with scRNA-seq from patient PDAC tumor, our results revealed that these dysregulated miRNAs were closely associated with extracellular matrix (ECM) remodeling, cell-ECM communication, epithelial-mesenchymal transition, as well as immunosuppression orchestrated by different cellular components of TME. The findings of this study could assist the development of miRNA-based stromal targeting biomarkers or therapy for PDAC patients.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"6 1","pages":"pbad004"},"PeriodicalIF":5.3,"publicationDate":"2023-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9595475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Workup of difficult-to-treat asthma: implications from treatable traits. 难治性哮喘的检查:可治疗特征的意义。

IF 5.3 4区医学

Precision Clinical Medicine Pub Date : 2023-03-01 DOI: 10.1093/pcmedi/pbad003

Qing Zhang, Wen Wen Wu, Lei Li, Vanessa M McDonald, Yu Cheng Chen, Gang Wang, Peter G Gibson

{"title":"Workup of difficult-to-treat asthma: implications from treatable traits.","authors":"Qing Zhang, Wen Wen Wu, Lei Li, Vanessa M McDonald, Yu Cheng Chen, Gang Wang, Peter G Gibson","doi":"10.1093/pcmedi/pbad003","DOIUrl":"https://doi.org/10.1093/pcmedi/pbad003","url":null,"abstract":"Traditional stepwise approach usually adjusts the treatment regimen based on changes in asthma symptoms and severity to achieve good asthma control. However, due to the generalized heterogeneity and complexity of asthma, its therapeutic efficacy in difficult-to-treat asthma is limited. Recently, a precision medicine approach based on the identification and intervention of treatable traits of chronic airway disease has been proposed and appears to be of greater benefit to asthmatics. We reported a 71-year-old male with uncontrolled asthma and multiple exacerbations over the past year. He complained of persistent dyspnea despite high-dose of inhaled corticosteroids plus other controllers. Does this patient have some potential treatable traits contributing to difficult-to-treat asthma? Through a multidimensional assessment of three domains including pulmonary, extrapulmonary, and behavioral/risk factors, 15 treatable traits were identified in the patient, mainly including airflow limitation, eosinophilic airway inflammation, small airway dysfunction, exacerbation prone, dilated cardiomyopathy, diabetes mellitus, inhaler device polypharmacy, smoking, and the absence of an asthma action plan. After targeted treatment for these treatable traits, the patient experienced significant improvement in dyspnea and he could maintain good asthma control with low-dose inhaled corticosteroids and long-acting β2-agonist. This study shows that, in response to the limitation of a stepwise approach to therapy, treatable traits is a new strategy where patients are individually assessed for a specified set of treatable problems, and an individualized treatment program is developed and implemented based on this multidimensional assessment, especially for difficult-to-treat asthma.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"6 1","pages":"pbad003"},"PeriodicalIF":5.3,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c9/91/pbad003.PMC10037422.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9274915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

CAS Array: design and assessment of a genotyping array for Chinese biobanking. CAS阵列:中国生物库基因分型阵列的设计与评价。

IF 5.3 4区医学

Precision Clinical Medicine Pub Date : 2023-03-01 DOI: 10.1093/pcmedi/pbad002

Zijian Tian, Fei Chen, Jing Wang, Benrui Wu, Jian Shao, Ziqing Liu, Li Zheng, You Wang, Tao Xu, Kaixin Zhou

{"title":"CAS Array: design and assessment of a genotyping array for Chinese biobanking.","authors":"Zijian Tian, Fei Chen, Jing Wang, Benrui Wu, Jian Shao, Ziqing Liu, Li Zheng, You Wang, Tao Xu, Kaixin Zhou","doi":"10.1093/pcmedi/pbad002","DOIUrl":"https://doi.org/10.1093/pcmedi/pbad002","url":null,"abstract":"Abstract Background Chronic diseases are becoming a critical challenge to the aging Chinese population. Biobanks with extensive genomic and environmental data offer opportunities to elucidate the complex gene–environment interactions underlying their aetiology. Genome-wide genotyping array remains an efficient approach for large-scale genomic data collection. However, most commercial arrays have reduced performance for biobanking in the Chinese population. Materials and methods Deep whole-genome sequencing data from 2 641 Chinese individuals were used as a reference to develop the CAS array, a custom-designed genotyping array for precision medicine. Evaluation of the array was performed by comparing data from 384 individuals assayed both by the array and whole-genome sequencing. Validation of its mitochondrial copy number estimating capacity was conducted by examining its association with established covariates among 10 162 Chinese elderly. Results The CAS Array adopts the proven Axiom technology and is restricted to 652 429 single-nucleotide polymorphism (SNP) markers. Its call rate of 99.79% and concordance rate of 99.89% are both higher than for commercial arrays. Its imputation-based genome coverage reached 98.3% for common SNPs and 63.0% for low-frequency SNPs, both comparable to commercial arrays with larger SNP capacity. After validating its mitochondrial copy number estimates, we developed a publicly available software tool to facilitate the array utility. Conclusion Based on recent advances in genomic science, we designed and implemented a high-throughput and low-cost genotyping array. It is more cost-effective than commercial arrays for large-scale Chinese biobanking.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"6 1","pages":"pbad002"},"PeriodicalIF":5.3,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9192775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Integrative analysis of ferroptosis regulators for clinical prognosis based on deep learning and potential chemotherapy sensitivity of prostate cancer. 基于深度学习和前列腺癌潜在化疗敏感性的铁下垂调节因子对临床预后的综合分析。

IF 5.3 4区医学

Precision Clinical Medicine Pub Date : 2023-03-01 DOI: 10.1093/pcmedi/pbad001

Tuanjie Guo, Zhihao Yuan, Tao Wang, Jian Zhang, Heting Tang, Ning Zhang, Xiang Wang, Siteng Chen

{"title":"Integrative analysis of ferroptosis regulators for clinical prognosis based on deep learning and potential chemotherapy sensitivity of prostate cancer.","authors":"Tuanjie Guo, Zhihao Yuan, Tao Wang, Jian Zhang, Heting Tang, Ning Zhang, Xiang Wang, Siteng Chen","doi":"10.1093/pcmedi/pbad001","DOIUrl":"https://doi.org/10.1093/pcmedi/pbad001","url":null,"abstract":"Exploring useful prognostic markers and developing a robust prognostic model for patients with prostate cancer are crucial for clinical practice. We applied a deep learning algorithm to construct a prognostic model and proposed the deep learning-based ferroptosis score (DLFscore) for the prediction of prognosis and potential chemotherapy sensitivity in prostate cancer. Based on this prognostic model, there was a statistically significant difference in the disease-free survival probability between patients with high and low DLFscore in the The Cancer Genome Atlas (TCGA) cohort (P < 0.0001). In the validation cohort GSE116918, we also observed a consistent conclusion with the training set (P = 0.02). Additionally, functional enrichment analysis showed that DNA repair, RNA splicing signaling, organelle assembly, and regulation of centrosome cycle pathways might regulate prostate cancer through ferroptosis. Meanwhile, the prognostic model we constructed also had application value in predicting drug sensitivity. We predicted some potential drugs for the treatment of prostate cancer through AutoDock, which could potentially be used for prostate cancer treatment.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"6 1","pages":"pbad001"},"PeriodicalIF":5.3,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/10/40/pbad001.PMC9982702.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10848453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Circulating metabolic signatures of heart failure in precision cardiology. 精准心脏病学中心力衰竭的循环代谢特征。

IF 5.3 4区医学

Precision Clinical Medicine Pub Date : 2023-03-01 DOI: 10.1093/pcmedi/pbad005

Huijing Xie, Bowen Zhang, Maodi Xie, Tao Li

{"title":"Circulating metabolic signatures of heart failure in precision cardiology.","authors":"Huijing Xie, Bowen Zhang, Maodi Xie, Tao Li","doi":"10.1093/pcmedi/pbad005","DOIUrl":"https://doi.org/10.1093/pcmedi/pbad005","url":null,"abstract":"Precision cardiology aims to implement personalized health care and precise medical decisions based on the specific characteristics of individuals. Metabolic remodeling plays a causal role in the pathogenesis of heart failure (HF). Changes in metabolic pathways such as substrate preference, high-energy phosphate metabolism and amino acid metabolism, are involved in pathological structural remodeling and functional impairment. These metabolic alterations are usually not restricted in the cardiac tissue, but also manifest in circulation. In clinical practice, blood sample is routinely used for HF screening. Metabolomics is an emerging omics technology that provides an efficient way to acquire dynamic metabolic profiles in circulation. An increasing number of metabolic biomarkers have been implicated in disease progression, making it possible to fight HF in a more effective and precise way. This review summarizes the modern analytical techniques in metabolomics as well as emerging circulating metabolites during the pathogenesis of HF, aiming to provide new insights into the prevention, diagnosis and treatment of HF in the era of precision medicine.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"6 1","pages":"pbad005"},"PeriodicalIF":5.3,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a1/7e/pbad005.PMC10068425.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9257804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Single-cell transcriptome profiling of the vaginal epithelium reveals the heterogeneity of suprabasal cells. 阴道上皮的单细胞转录组分析揭示了基底上细胞的异质性。

IF 5.3 4区医学

Precision Clinical Medicine Pub Date : 2023-03-01 DOI: 10.1093/pcmedi/pbad006

Chen Liang, Zixian Zhao, Sarah Liu, Ting Zhang, Wei Zuo

{"title":"Single-cell transcriptome profiling of the vaginal epithelium reveals the heterogeneity of suprabasal cells.","authors":"Chen Liang, Zixian Zhao, Sarah Liu, Ting Zhang, Wei Zuo","doi":"10.1093/pcmedi/pbad006","DOIUrl":"https://doi.org/10.1093/pcmedi/pbad006","url":null,"abstract":"The integrity of the vaginal epithelium is crucial for women’s reproductive health and for providing protection against HIV and sexually transmitted infections. 1 The vagina is a tubular tract made of fibromuscular and elastic tissue that connects the cervix to the outer genitals. Its main function is to discharge uterine secretions. 2 The vaginal epithelium (VE) is a keratinized, stratified squamous epithelium consisting of three layers: the basal layer, the suprabasal layer, and the apical cornified layer. 3 Estrogens induce the proliferation of basal epithelial cells in the vagina. The suprabasal cells, which are no longer mitogenic, differentiate as they move up through the epithelium. The apical cells undergo keratinization, lose their nuclei and cytoplasm, and eventually shed from the surface. 4 With multiple sexually transmitted diseases posing a significant threat to human health, 5 it is increasingly important to understand how the vaginal epithelium regenerates to maintain homeostasis and how it differs from the neighboring cervical epithelium. In this study, we extracted vaginal tissue from five adult virgin mice and conducted single-cell RNA sequencing (scRNA-seq) on the vaginal epithelium. We obtained a total of 7823 cells and isolated and sequenced","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"6 1","pages":"pbad006"},"PeriodicalIF":5.3,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9595474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

GLUE multimodal single cell data. GLUE多模态单细胞数据。

IF 5.3 4区医学

Precision Clinical Medicine Pub Date : 2023-03-01 DOI: 10.1093/pcmedi/pbad007

Weizhong Li, Chaoyu Yan

引用次数: 0

Patient-derived organoids potentiate precision medicine in advanced clear cell renal cell carcinoma. 患者来源的类器官增强了晚期透明细胞肾细胞癌的精准治疗。

IF 5.3 4区医学

Precision Clinical Medicine Pub Date : 2022-12-01 DOI: 10.1093/pcmedi/pbac028

Yizheng Xue, Bingran Wang, Yiying Tao, Jun Xia, Kedi Yuan, Junhua Zheng, Wei Zhai, Wei Xue

{"title":"Patient-derived organoids potentiate precision medicine in advanced clear cell renal cell carcinoma.","authors":"Yizheng Xue, Bingran Wang, Yiying Tao, Jun Xia, Kedi Yuan, Junhua Zheng, Wei Zhai, Wei Xue","doi":"10.1093/pcmedi/pbac028","DOIUrl":"https://doi.org/10.1093/pcmedi/pbac028","url":null,"abstract":"To investigate the role of patient-derived organoid (PDO) model in the precision medicine of advanced clear cell renal cell carcinoma (ccRCC), we retrospectively analyzed the clinical data of seven cases of ccRCC diagnosed by operation and pathology in Renji Hospital from September 2021 to September 2022. The seven patients were diagnosed with advanced ccRCC with or without remote metastasis. Cytoreductive and radical nephrectomy was performed respectively. To predict the response to immunotherapy and provide personalized medicine recommendation, a PDO model based on air-liquid interface system was established from the surgical resected tumor and subsequent drug screening was performed. Hematoxylin and eosin (H&E) staining and immunohistochemistry revealed that the PDO recapitulated the histological feature of parent tumor. Immunofluorescence staining identified that CD3+ T cells, SMA+ cancer associated fibroblasts, and CD31+ endothelial cells were preserved in PDO models. Fluorescence activated cell sorter (FACS) revealed an evidently increased ratio of CD8+/CD4+ T cells and apoptotic tumor cells in PDO treated with toripalimab than those treated with IgG4. The results showed that toripalimab is able to rescue the excessive death of CD8+ T cells by critically reversing the immune exhaustion state of ccRCC in PDO model. This research validated that PDO is a promising and faithful preclinical model for prediction of immunotherapy response in patients with ccRCC.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"5 4","pages":"pbac028"},"PeriodicalIF":5.3,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10411140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Expanding antiviral therapy indications for HBeAg-negative chronic hepatitis B patients with normal ALT and positive HBV DNA. 扩大丙肝抗原阴性慢性乙型肝炎患者ALT正常和HBV DNA阳性的抗病毒治疗适应症。

IF 5.3 4区医学

Precision Clinical Medicine Pub Date : 2022-12-01 DOI: 10.1093/pcmedi/pbac030

Jing Zhou, Fada Wang, Lanqing Li, Enqiang Chen

{"title":"Expanding antiviral therapy indications for HBeAg-negative chronic hepatitis B patients with normal ALT and positive HBV DNA.","authors":"Jing Zhou, Fada Wang, Lanqing Li, Enqiang Chen","doi":"10.1093/pcmedi/pbac030","DOIUrl":"https://doi.org/10.1093/pcmedi/pbac030","url":null,"abstract":"With the improved efficacy and accessibility of antiviral agents as well as the concerns about disease progression, there is a hot discussion on whether HBeAg-negative chronic hepatitis B (CHB) patients with normal alanine aminotransferase (ALT) and positive HBV DNA should be treated. According to the international guidelines on the stages of the natural history of HBV infection, HBeAg-negative CHB patients with normal ALT and positive HBV DNA can be divided into two groups: one is the well-known \"inactive carrier phase\", which is defined as serum HBV DNA < 2000 IU/ml and no significant liver inflammation; and the other is the \"indeterminate phase\", which is defined as serum HBV DNA ≥ 2000 IU/mL regardless of the pathological changes in liver tissue, or HBV DNA < 2000 IU/mL but accompanied by significant pathological changes in the liver. In this minireview, we will expound the disease characteristics, disease progression, and clinical management status of these two groups. Based on the analysis, we propose that HBeAg-negative patients with normal ALT but detectable serum HBV DNA should be treated, regardless of their age, family history of hepatocellular carcinoma (HCC) or the severity of liver necroinflammation. Expanding the indications of antiviral therapy will help improve the survival and quality of life of patients by preventing disease progression, and consequently reduce the risk of HCC development.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"5 4","pages":"pbac030"},"PeriodicalIF":5.3,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f7/23/pbac030.PMC9745772.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10731592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Recent advances in small-molecular therapeutics for COVID-19. 新冠肺炎小分子治疗的最新进展。

IF 5.3 4区医学

Precision Clinical Medicine Pub Date : 2022-12-01 DOI: 10.1093/pcmedi/pbac024

Lei Zhong, Zhipeng Zhao, Xuerun Peng, Jun Zou, Shengyong Yang

{"title":"Recent advances in small-molecular therapeutics for COVID-19.","authors":"Lei Zhong, Zhipeng Zhao, Xuerun Peng, Jun Zou, Shengyong Yang","doi":"10.1093/pcmedi/pbac024","DOIUrl":"https://doi.org/10.1093/pcmedi/pbac024","url":null,"abstract":"The COVID-19 pandemic poses a fundamental challenge to global health. Since the outbreak of SARS-CoV-2, great efforts have been made to identify antiviral strategies and develop therapeutic drugs to combat the disease. There are different strategies for developing small molecular anti-SARS-CoV-2 drugs, including targeting coronavirus structural proteins (e.g. spike protein), non-structural proteins (nsp) (e.g. RdRp, Mpro, PLpro, helicase, nsp14, and nsp16), host proteases (e.g. TMPRSS2, cathepsin, and furin) and the pivotal proteins mediating endocytosis (e.g. PIKfyve), as well as developing endosome acidification agents and immune response modulators. Favipiravir and chloroquine are the anti-SARS-CoV-2 agents that were identified earlier in this epidemic and repurposed for COVID-19 clinical therapy based on these strategies. However, their efficacies are controversial. Currently, three small molecular anti-SARS-CoV-2 agents, remdesivir, molnupiravir, and Paxlovid (PF-07321332 plus ritonavir), have been granted emergency use authorization or approved for COVID-19 therapy in many countries due to their significant curative effects in phase III trials. Meanwhile, a large number of promising anti-SARS-CoV-2 drug candidates have entered clinical evaluation. The development of these drugs brings hope for us to finally conquer COVID-19. In this account, we conducted a comprehensive review of the recent advances in small molecule anti-SARS-CoV-2 agents according to the target classification. Here we present all the approved drugs and most of the important drug candidates for each target, and discuss the challenges and perspectives for the future research and development of anti-SARS-CoV-2 drugs.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"5 4","pages":"pbac024"},"PeriodicalIF":5.3,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cb/d0/pbac024.PMC9579963.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9181205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9